Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Weighted Average) (2017 - 2026)

Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) history runs 10 years deep, the most recent figure standing at $104.1 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 11.81% year-over-year to $104.1 million; the TTM figure through Mar 2026 stood at $104.1 million (up 11.81% YoY), while the FY2025 annual figure was $94.1 million, up 16.43% from the prior year.
• Shares Outstanding (Weighted Average) was $104.1 million for Q1 2026 at Crinetics Pharmaceuticals, up from $94.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $104.1 million in Q1 2026 to a low of $47.7 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $71.5 million across 5 years, with a median of $72.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) jumped 49.86% in 2022, then advanced 2.99% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $52.0 million in 2022, then increased by 11.71% to $58.1 million in 2023, then jumped by 39.11% to $80.8 million in 2024, then advanced by 16.43% to $94.1 million in 2025, then climbed by 10.68% to $104.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $104.1 million (Q1 2026), $94.1 million (Q4 2025), and $93.7 million (Q3 2025), per Business Quant data.